Macular Edema, Cystoid Clinical Trial
Official title:
Intraretinal Cystoid Changes After Vitrectomy With Membrane Peeling
NCT number | NCT04472039 |
Other study ID # | RAC |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 30, 2020 |
Est. completion date | September 28, 2020 |
Verified date | September 2020 |
Source | Vienna Institute for Research in Ocular Surgery |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Aim of the study is to assess the rate of postoperative intraretinal cystoid changes after pars plana vitrectomy with membrane peeling and peribulbar application of triamcinolone acetonide and to examine possible risk factors for postoperative intraretinal cystoid changes.
Status | Completed |
Enrollment | 40 |
Est. completion date | September 28, 2020 |
Est. primary completion date | September 28, 2020 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - presence of an ERM - indication for membrane peeling defined as significant loss of vision and/or metamorphopsia due to the ERM - application of periocular triamcinolone acetonide at the end of surgery - at least one follow-up examination present in the patient's history Exclusion Criteria: - macular edema caused by conditions other than ERM (such as choroidal neovascularization, diabetic macular edema, etc.) |
Country | Name | City | State |
---|---|---|---|
Austria | Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna | Vienna |
Lead Sponsor | Collaborator |
---|---|
Vienna Institute for Research in Ocular Surgery |
Austria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intraretinal cystoid changes | presence of intraretinal cystoid changes in OCT is assessed during the time period of 3 months after surgery | 3 months | |
Secondary | intraocular pressure (IOP) | intraocular pressure is examined during the time period of 3 months after surgery | 3 months | |
Secondary | distance corrected visual acuity | distance corrected visual acuity is measured at baseline and 3 months after surgery | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03559491 -
Dexamethasone Intravitreal Implant in Retinal Vein Occlusion
|
||
Completed |
NCT00105027 -
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study
|
Phase 3 | |
Completed |
NCT01546402 -
Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
|
Phase 4 | |
Completed |
NCT00106132 -
Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage
|
Phase 3 | |
Completed |
NCT00335439 -
Effect of Prophylactic Ketorolac on CME After Cataract Surgery
|
N/A | |
Terminated |
NCT02665689 -
Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab
|
Phase 4 | |
Completed |
NCT01698749 -
Effect of Intravitreal Long Acting Dexamethasone Implant, Ozurdex in Patients With Diabetic Macular Edema
|
N/A | |
Completed |
NCT00000115 -
Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema
|
Phase 2 | |
Withdrawn |
NCT00135655 -
A Study of Denufosol Tetrasodium Intravitreal Injection in Subjects With Post Cataract Extraction Macular Edema
|
Phase 2 | |
Completed |
NCT00001738 -
Vascular Endothelial Growth Factor (VEGF) in Uveitis
|
N/A |